Last reviewed · How we verify

Epilepsy characterized by intractable complex partial seizures — Treatment Landscape & Competitive Intelligence

Epilepsy characterized by intractable complex partial seizures (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Epilepsy characterized by intractable complex partial seizures, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Keppra levetiracetam Generic (originally UCB Pharma) Antiepileptic agent Synaptic vesicle protein SV2A 1999-11-30
Gabitril TIAGABINE Cephalon Anti-epileptic Agent Sodium- and chloride-dependent GABA transporter 1 1997-01-01
Cerebyx FOSPHENYTOIN Pfizer Anti-epileptic Agent Sodium channel protein type 5 subunit alpha 1996-01-01
Depakene valproic acid Generic (originally Abbott/AbbVie) Anti-epileptic Agent [EPC] Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2 1978-02-28
Tegretol carbamazepine Novartis AG (originally Geigy) Mood Stabilizer [EPC] Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4 1968-03-11
Peganone ETHOTOIN Recordati Anti-epileptic Agent Sodium channel alpha subunit 1957-01-01
Mysoline PRIMIDONE Bausch Health Anti-epileptic Agent [EPC] Transient receptor potential cation channel subfamily M member 3 1954-01-01
Phenytoin Sodium PHENYTOIN Viatris Anti-epileptic Agent Sodium channel protein type 2 subunit alpha 1953-01-01
Dilantin Phenytoin Sodium Pfizer phenytoin Nuclear receptor subfamily 1 group I member 3 1953-01-01
Phenurone PHENACEMIDE Abbvie Sodium channel protein type 1 subunit alpha 1951-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in Epilepsy characterized by intractable complex partial seizures
  2. Ataturk University · 1 drug in Epilepsy characterized by intractable complex partial seizures
  3. Bausch Health · 1 drug in Epilepsy characterized by intractable complex partial seizures
  4. Cephalon · 1 drug in Epilepsy characterized by intractable complex partial seizures
  5. Enanta Pharmaceuticals, Inc · 1 drug in Epilepsy characterized by intractable complex partial seizures
  6. GSK · 1 drug in Epilepsy characterized by intractable complex partial seizures
  7. Generic (originally Abbott/AbbVie) · 1 drug in Epilepsy characterized by intractable complex partial seizures
  8. Generic (originally UCB Pharma) · 1 drug in Epilepsy characterized by intractable complex partial seizures
  9. Institute of Child Health · 1 drug in Epilepsy characterized by intractable complex partial seizures
  10. Janssen · 1 drug in Epilepsy characterized by intractable complex partial seizures
  11. Masonic Cancer Center, University of Minnesota · 1 drug in Epilepsy characterized by intractable complex partial seizures
  12. Novartis · 1 drug in Epilepsy characterized by intractable complex partial seizures

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Epilepsy characterized by intractable complex partial seizures:

Cite this brief

Drug Landscape (2026). Epilepsy characterized by intractable complex partial seizures — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/epilepsy-characterized-by-intractable-complex-partial-seizures. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing